Table 3 Cox regression analyses of decrease rate of clinical parameters after 1 year of treatment for prediction of HBeAg seroconversion at year 5.

From: Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment

Variables

HR (95% CI)

p value

Univariate analysis

 Sex (Femal vs. Male)

2.030 (0.679–6.068)

0.205

 Age

0.991 (0.941–1.044)

0.730

 HBV genotype (Non-C vs. C)

0.531 (0.305–1.146)

0.240

 Cirrhosis (Yes vs. No)a

1.353 (0.537–3.410)

0.522

 Metavir scorea

1.003 (0.702–1.431)

0.980

 TB

0.999 (0.983–1.015)

0.889

 ALT

0.998 (0.980–1.016)

0.811

 AST

0.992 (0.968–1.018)

0.548

 HBsAg

0.472 (0.219–1.018)

0.056

 HBeAg

1.014 (0.979–1.051)

0.439

 HBV DNAa

0.688 (0.552–0.859)

0.004

 IL-4

0.997 (0.981–1.012)

0.666

 IL-6

0.987 (0.970–1.004)

0.140

 IL-8

0.986 (0.970–1.002)

0.078

 IFN-γ

0.992 (0.974–1.010)

0.385

 IP-10

0.976 (0.959–0.994)

0.008

 MIP-1α

0.996 (0.979–1.013)

0.654

 PDGF-BB

0.997 (0.980–1.015)

0.781

 MIP-1β

0.997 (0.980–1.014)

0.753

 RANTES

1.016 (0.973–1.060)

0.482

Multivariate analysis

 HBsAg

0.481 (0.200–1.105)

0.084

 HBV DNAa

0.686 (0.430–1.097)

0.116

 IL-8

0.993 (0.981–1.006)

0.314

 IP-10

0.972 (0.948–0.996)

0.012

  1. aLiver biopsy or HBV DNA levels before ETV therapy; HR: hazard ratio; CI: confidence interval.
Back to article page